{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:15Z","timestamp":1790388975779,"version":"4.1.0"},"reference-count":219,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajps.2025.101068","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:42:17Z","timestamp":1748400137000},"page":"101068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrating CRISPR\/Cas technology with clinical trials: Principles, progress and challenges"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-6233","authenticated-orcid":false,"given":"Piao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Khoshandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Bhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Soltaninejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Hosseinkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Sheykhhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","article-title":"Clinical applications of the CRISPR\/Cas9 genome-editing system: delivery options and challenges in precision medicine","volume":"11","author":"Khoshandam","year":"2024","journal-title":"Genes Dis"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0002","first-page":"777","article-title":"CRISPR-Cas9: a history of its discovery and ethical considerations of its use in genome editing","volume":"87","author":"Gostimskaya","year":"2022","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0003","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2958.1993.tb01721.x","article-title":"Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites","volume":"9","author":"Mojica","year":"1993","journal-title":"Mol Microbiol"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01397-17","article-title":"The CRISPR spacer space is dominated by sequences from species-specific mobilomes","volume":"8","author":"Shmakov","year":"2017","journal-title":"MBio"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR-Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"15","key":"10.1016\/j.ajps.2025.101068_bib0006","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ajps.2025.101068_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147334","article-title":"Recent progress in CRISPR\/Cas9-based genome editing for enhancing plant disease resistance","volume":"866","author":"Boubakri","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.ajps.2025.101068_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.pmbts.2021.01.015","article-title":"Modulating Cas9 activity for precision gene editing","volume":"181","author":"Uslu","year":"2021","journal-title":"Prog Mol Biol Transl"},{"key":"10.1016\/j.ajps.2025.101068_bib0009","first-page":"254","article-title":"Genetic scissors\" CRISPR\/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair","volume":"22","author":"Li","year":"2023","journal-title":"Bioact Mater"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","article-title":"DNA repair pathway choices in CRISPR-Cas9-mediated genome editing","volume":"37","author":"Xue","year":"2021","journal-title":"Trends Genet"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0011","article-title":"CAR-T, and NK: current applications and future perspectives","volume":"11","author":"Khoshandam","year":"2024","journal-title":"Genes Dis"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0012","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/acsabm.1c01112","article-title":"Smart strategies for precise delivery of CRISPR\/Cas9 in genome editing","volume":"5","author":"Hasanzadeh","year":"2022","journal-title":"ACS Appl Bio Mater"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tibtech.2017.07.007","article-title":"Advances in industrial biotechnology using CRISPR-Cas systems","volume":"36","author":"Donohoue","year":"2018","journal-title":"Trends Biotechnol"},{"issue":"11","key":"10.1016\/j.ajps.2025.101068_bib0014","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41580-020-00288-9","article-title":"Applications of CRISPR-Cas in agriculture and plant biotechnology","volume":"21","author":"Zhu","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajps.2025.101068_bib0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-981-19-5642-3_20","article-title":"Enabling precision medicine with CRISPR-Cas genome editing technology: a translational perspective","volume":"1396","author":"Ilahibaks","year":"2023","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drudis.2022.103375","article-title":"CRISPR\/Cas9 in the era of nanomedicine and synthetic biology","volume":"28","author":"Schmidt","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ajps.2025.101068_bib0017","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijbiomac.2022.11.018","article-title":"CRISPR\/Cas9 as precision and high-throughput genetic engineering tools in gastrointestinal cancer research and therapy","volume":"223","author":"Hosseini","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.ajps.2025.101068_bib0018","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jconrel.2022.09.046","article-title":"Brain-targeted CRISPR\/Cas9 nanomedicine for effective glioblastoma therapy","volume":"351","author":"Ruan","year":"2022","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.ajps.2025.101068_bib0019","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1021\/acssynbio.3c00278","article-title":"Development of CRISPR\/Cas9-based genome editing tools for polyploid yeast Cyberlindnera jadinii and its application in engineering heterologous steroid-producing strains","volume":"12","author":"Gu","year":"2023","journal-title":"ACS Synth Biol"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acscentsci.2c01467","article-title":"Glow-in-the-dark infectious disease diagnostics using CRISPR-Cas9-based split luciferase complementation","volume":"9","author":"van der Veer","year":"2023","journal-title":"ACS Cent Sci"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40476-7","article-title":"Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo","volume":"14","author":"Tao","year":"2023","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.ajps.2025.101068_bib0022","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","article-title":"Engineered extracellular vesicle-delivered CRISPR\/Cas9 for radiotherapy sensitization of glioblastoma","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.ajps.2025.101068_bib0023","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.1021\/acsnano.4c01400","article-title":"Context-responsive nanoparticle derived from synthetic zwitterionic ionizable phospholipids in targeted CRISPR\/Cas9 therapy for basal-like breast cancer","volume":"18","author":"Moitra","year":"2024","journal-title":"ACS Nano"},{"issue":"17","key":"10.1016\/j.ajps.2025.101068_bib0024","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1021\/acs.nanolett.3c01914","article-title":"Steerable microneedles enabling deep delivery of photosensitizers and CRISPR\/Cas9 systems for effective combination cancer therapy","volume":"23","author":"Wang","year":"2023","journal-title":"Nano Lett"},{"key":"10.1016\/j.ajps.2025.101068_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106480","article-title":"CRISPR\/CAS9: a promising approach for the research and treatment of cardiovascular diseases","volume":"185","author":"Dong","year":"2022","journal-title":"Pharmacol Res"},{"issue":"25","key":"10.1016\/j.ajps.2025.101068_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300195","article-title":"Progress and perspective of CRISPR-Cas9 technology in translational medicine","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv Sci"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0027","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0028","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.3390\/pharmaceutics16070906","article-title":"Casgevy: innovative medicinal products require innovative approaches to regulatory assessment","volume":"16","author":"Kerwash","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0029","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann Med Surg"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40291-024-00696-z","article-title":"Exagamglogene autotemcel: first approval","volume":"28","author":"Hoy","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.ajps.2025.101068_bib0031","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JBM.S477507","article-title":"Newer modalities and updates in the management of sickle cell disease: a systematic review","volume":"15","author":"Patel","year":"2024","journal-title":"J Blood Med"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0032","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.amjmed.2023.12.018","article-title":"CRISPR therapy of sickle cell disease: the dawning of the gene editing era","volume":"137","author":"Adashi","year":"2024","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajps.2025.101068_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.135116","article-title":"Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery","volume":"435","author":"Tang","year":"2022","journal-title":"Chem Eng J"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0035","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1038\/s41467-022-30515-0","article-title":"CRISPR\/Cas9 gRNA activity depends on free energy changes and on the target PAM context","volume":"13","author":"Corsi","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ajps.2025.101068_bib0036","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bbamcr.2016.06.009","article-title":"remove or replace: a highly advanced genome editing system using CRISPR\/Cas9","volume":"1863","author":"Ceasar","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"36","key":"10.1016\/j.ajps.2025.101068_bib0037","doi-asserted-by":"crossref","first-page":"11142","DOI":"10.1021\/jacs.8b05469","article-title":"Sharpening the scissors: mechanistic details of CRISPR\/Cas9 improve functional understanding and inspire future research","volume":"140","author":"Raper","year":"2018","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0038","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1038\/s41467-022-34213-9","article-title":"Automated identification of sequence-tailored Cas9 proteins using massive metagenomic data","volume":"13","author":"Ciciani","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0039","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41467-020-20633-y","article-title":"CRISPR technologies and the search for the PAM-free nuclease","volume":"12","author":"Collias","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2025.101068_bib0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.pmbts.2024.08.001","article-title":"CRISPR challenges in clinical developments","volume":"210","author":"Khoshandam","year":"2025","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0041","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1038\/s41467-022-30515-0","article-title":"CRISPR\/Cas9 gRNA activity depends on free energy changes and on the target PAM context","volume":"13","author":"Corsi","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0042","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41587-022-01410-2","article-title":"High-throughput continuous evolution of compact Cas9 variants targeting single-nucleotide-pyrimidine PAMs","volume":"41","author":"Huang","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0043","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ajps.2025.101068_bib0044","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1021\/acssynbio.3c00466","article-title":"Development of a CRISPR\/Cas9D10A nickase (nCas9)-mediated genome editing tool in streptomyces","volume":"12","author":"Ma","year":"2023","journal-title":"ACS Synth Biol"},{"issue":"23","key":"10.1016\/j.ajps.2025.101068_bib0045","doi-asserted-by":"crossref","first-page":"e6041","DOI":"10.3390\/ijms20236041","article-title":"Dead Cas systems: types, principles, and applications","volume":"20","author":"Brezgin","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.ajps.2025.101068_bib0046","doi-asserted-by":"crossref","first-page":"e6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0047","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41434-023-00434-w","article-title":"CRISPR\/Cas9-mediated base editors and their prospects for mitochondrial genome engineering","volume":"31","author":"Eghbalsaied","year":"2024","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajps.2025.101068_bib0048","series-title":"A roadmap for plant genome editing","first-page":"17","article-title":"Base editing and prime editing","author":"Kaya","year":"2024"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0049","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-023-37507-8","article-title":"Prime editing with genuine Cas9 nickases minimizes unwanted indels","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.tibtech.2023.03.004","article-title":"Prime editing: advances and therapeutic applications","volume":"41","author":"Zhao","year":"2023","journal-title":"Trends Biotechnol"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0051","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol Biotechnol"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0052","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12033-021-00422-8","article-title":"CRISPR\/Cas-based modifications for therapeutic applications: a review","volume":"64","author":"Bharathkumar","year":"2022","journal-title":"Mol Biotechnol"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0053","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1002\/wrna.1694","article-title":"Applications of the versatile CRISPR-Cas13 RNA targeting system","volume":"13","author":"Kordys","year":"2022","journal-title":"Wires RNA"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0054","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41433-022-02169-1","article-title":"The application and progression of CRISPR\/Cas9 technology in ophthalmological diseases","volume":"37","author":"Hu","year":"2023","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0055","first-page":"36","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"TX","year":"2023","journal-title":"Signal Transduct Tar"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0056","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-023-01738-6","article-title":"Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"issue":"24","key":"10.1016\/j.ajps.2025.101068_bib0057","doi-asserted-by":"crossref","first-page":"24632","DOI":"10.1021\/acsnano.3c03267","article-title":"Multifunctional clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based nanobomb against carbapenem-resistant Acinetobacter baumannii infection through cascade reaction and amplification synergistic effect","volume":"17","author":"Li","year":"2023","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0058","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12035-021-02638-w","article-title":"CRISPR-Cas9-mediated gene therapy in neurological disorders","volume":"59","author":"Guan","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"11","key":"10.1016\/j.ajps.2025.101068_bib0059","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1021\/acsnano.3c05864","article-title":"Ultrasound-assisted CRISPRi-exosome for epigenetic modification of \u03b1-synuclein gene in a mouse model of Parkinson's disease","volume":"18","author":"Kong","year":"2024","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0060","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13311-022-01197-9","article-title":"CRISPR-Cas9 gene therapy for duchenne muscular dystrophy","volume":"19","author":"Mbakam","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0061","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","article-title":"Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease","volume":"7","author":"Yan","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.ajps.2025.101068_bib0062","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202401353","article-title":"Current advances and material innovations in the search for novel treatments of phenylketonuria","author":"Delbreil","year":"2024","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00438-022-01978-z","article-title":"CRISPR\/Cas9, a promising approach for the treatment of \u03b2-thalassemia: a systematic review","volume":"298","author":"Khiabani","year":"2023","journal-title":"Mol Genet Genomics"},{"key":"10.1016\/j.ajps.2025.101068_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147480","article-title":"CRISPR\/Cas9-based gene-editing technology for sickle cell disease","volume":"874","author":"Ma","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.ajps.2025.101068_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1065377","article-title":"Clinical genome editing to treat sickle cell disease-a brief update","volume":"9","author":"Zarghamian","year":"2023","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0066","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/molecules30020385","article-title":"Hemoglobin variants as targets for stabilizing drugs","volume":"30","author":"\u017dold\u00e1kov\u00e1","year":"2025","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0067","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-022-01237-z","article-title":"Advances in the diagnosis and treatment of sickle cell disease","volume":"15","author":"Brandow","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ajps.2025.101068_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101185","article-title":"Revolutionising healing: gene editing's breakthrough against sickle cell disease","volume":"65","author":"Dimitrievska","year":"2024","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0069","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ajps.2025.101068_bib0070","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2025.101068_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.880752","article-title":"New insights into pathophysiology of \u03b2-thalassemia","volume":"9","author":"Sanchez-Villalobos","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0072","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjh.17897","article-title":"Primary HBB gene mutation severity and long-term outcomes in a global cohort of \u03b2-thalassaemia","volume":"196","author":"Musallam","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ajps.2025.101068_bib0073","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/j.ymthe.2024.07.022","article-title":"Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease","volume":"32","author":"Katta","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2025.101068_bib0074","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.2147\/OPTH.S370032","article-title":"Current and future treatment of retinitis pigmentosa","volume":"16","author":"Cross","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajps.2025.101068_bib0075","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/bjo-2022-321903","article-title":"Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes","volume":"107","author":"Varela","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"22","key":"10.1016\/j.ajps.2025.101068_bib0076","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1111\/febs.16771","article-title":"Therapeutic applications of CRISPR\/Cas9 gene editing technology for the treatment of ocular diseases","volume":"290","author":"Sundaresan","year":"2023","journal-title":"FEBS J"},{"issue":"9","key":"10.1016\/j.ajps.2025.101068_bib0077","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1002\/mco2.645","article-title":"Current developments of gene therapy in human diseases","volume":"5","author":"Liu","year":"2024","journal-title":"Medcomm"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0078","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bjophthalmol-2020-318483","article-title":"Leber congenital amaurosis\/early-onset severe retinal dystrophy: current management and clinical trials","volume":"106","author":"Varela","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0079","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","article-title":"CRISPR\/Cas9-mediated genome editing as a therapeutic approach for Leber congenital amaurosis 10","volume":"25","author":"Ruan","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ajps.2025.101068_bib0081","article-title":"ClinicalTrials.Gov","year":"2018","journal-title":"Safety and efficacy of EDIT-101 in LCA10"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0082","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1038\/s41467-023-43301-3","article-title":"Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis","volume":"14","author":"Steinebrei","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ajps.2025.101068_bib0083","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0084","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-020-00180-w","article-title":"Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years","volume":"9","author":"Merlini","year":"2020","journal-title":"Neurol Ther"},{"issue":"6","key":"10.1016\/j.ajps.2025.101068_bib0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajps.2025.101068_bib0086","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0087","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Mannucci PM. Hemophilia therapy: the future has begun","volume":"105","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0088","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0089","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40291-024-00705-1","article-title":"In vivo LNP-CRISPR approaches for the treatment of hemophilia","volume":"28","author":"Lee","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajps.2025.101068_bib0091","doi-asserted-by":"crossref","unstructured":"Khoshandam M, Bhia I, Soltaninejad H, Sani M, Hosseinkhani S, Hamidieh AA. CRISPR\/Cas9 from discoveryto clinical impact: a comprehensive review of history, mechanisms, applications, and future challenges [Preprint]. Authorea 2024. DOI: 10.22541\/au.172479318.85664954\/v1","DOI":"10.22541\/au.172479318.85664954\/v1"},{"key":"10.1016\/j.ajps.2025.101068_bib0092","doi-asserted-by":"crossref","DOI":"10.1080\/17474086.2025.2459253","article-title":"Could targeted gene insertion of factor 9 be a potential durable treatment for hemophilia B?","author":"Castaman","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ajps.2025.101068_bib0093","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27602","article-title":"2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders","author":"Jiang","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0094","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40291-024-00705-1","article-title":"In vivo LNP-CRISPR approaches for the treatment of hemophilia","volume":"28","author":"Lee","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0095","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41598-018-36506-w","article-title":"Effective CRISPR\/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair","volume":"9","author":"van de Vrugt","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajps.2025.101068_bib0096","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","article-title":"Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications","volume":"343","author":"Bhattacharjee","year":"2022","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0097","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.stem.2019.08.016","article-title":"NHEJ-mediated repair of CRISPR-Cas9-induced DNA breaks efficiently corrects mutations in HSPCs from patients with fanconi anemia","volume":"25","author":"Rom\u00e1n-Rodr\u00edguez","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ajps.2025.101068_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.817195","article-title":"Sleep disorders in Rett syndrome and Rett-related disorders: a narrative review","volume":"13","author":"Tascini","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.ajps.2025.101068_bib0099","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neubiorev.2020.12.025","article-title":"Patient-derived iPSC modeling of rare neurodevelopmental disorders: molecular pathophysiology and prospective therapies","volume":"121","author":"Sabitha","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.ajps.2025.101068_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1229553","article-title":"A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome","volume":"11","author":"Percy","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ajps.2025.101068_bib0101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fgene.2019.00625","article-title":"Efficient and precise CRISPR\/Cas9-mediated MECP2 modifications in human-induced pluripotent stem cells","volume":"10","author":"Le","year":"2019","journal-title":"Front Genet"},{"issue":"24","key":"10.1016\/j.ajps.2025.101068_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202306432","article-title":"Magnetic nanoparticle-assisted non-viral CRISPR-Cas9 for enhanced genome editing to treat Rett syndrome","volume":"11","author":"Cho","year":"2024","journal-title":"Adv Sci"},{"key":"10.1016\/j.ajps.2025.101068_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102457","article-title":"Advanced delivery systems for gene editing: a comprehensive review from the GenE-HumDi COST Action Working Group","volume":"36","author":"Cavazza","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JHD-200445","article-title":"What is the pathogenic CAG expansion length in Huntington's disease?","volume":"10","author":"Donaldson","year":"2021","journal-title":"J Huntingtons Dis"},{"issue":"11","key":"10.1016\/j.ajps.2025.101068_bib0105","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12264-022-00880-3","article-title":"CRISPR-based genome-editing tools for Huntington's disease research and therapy","volume":"38","author":"Qin","year":"2022","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.ajps.2025.101068_bib0106","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.ajps.2025.101068_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.992546","article-title":"Clinical and genetic characteristics of Chinese Duchenne\/Becker muscular dystrophy patients with small mutations","volume":"16","author":"Gan","year":"2022","journal-title":"Front Neurosci"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0108","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","article-title":"Duchenne muscular dystrophy: pathogenesis and promising therapies","volume":"270","author":"Chang","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0109","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3892\/etm.2021.9875","article-title":"Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy","volume":"21","author":"Zhang","year":"2021","journal-title":"Exp Ther Med"},{"issue":"9\u201310","key":"10.1016\/j.ajps.2025.101068_bib0111","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/hum.2023.053","article-title":"CRISPR-editing therapy for duchenne muscular dystrophy","volume":"34","author":"Chemello","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajps.2025.101068_bib0112","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s15010-020-01554-w","article-title":"CRISPR-based strategies in infectious disease diagnosis and therapy","volume":"49","author":"Binnie","year":"2021","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3349\/ymj.2022.63.2.105","article-title":"Basic principles and clinical applications of CRISPR-based genome editing","volume":"63","author":"Lim","year":"2022","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ajps.2025.101068_bib0114","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.omtm.2022.01.012","article-title":"CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice","volume":"24","author":"Li","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"13","key":"10.1016\/j.ajps.2025.101068_bib0115","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2025.101068_bib0116","series-title":"Nanotechnology in medicine: toxicity and safety","first-page":"195","article-title":"Gene delivery using nanocarriers: toxicity and safety aspects","author":"Vhora","year":"2021"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bfgp\/elaa001","article-title":"CRISPR\/Cas9 for cancer treatment: technology, clinical applications and challenges","volume":"19","author":"Cheng","year":"2020","journal-title":"Brief Funct Genomics"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0118","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1002\/mco2.495","article-title":"Epigenetic regulation in cancer","volume":"5","author":"Gu","year":"2024","journal-title":"Medcomm"},{"issue":"12","key":"10.1016\/j.ajps.2025.101068_bib0119","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1021\/acs.molpharmaceut.3c00610","article-title":"Advances in the delivery and development of epigenetic therapeutics for the treatment of cancer","volume":"20","author":"Ghosh","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajps.2025.101068_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.115722","article-title":"Doxorubicin-loaded micelles in tumor cell-specific chemotherapy","volume":"227","author":"Almajidi","year":"2023","journal-title":"Environ Res"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0121","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10555-023-10162-7","article-title":"Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response","volume":"43","author":"Ebrahimi","year":"2024","journal-title":"Cancer Metast Rev"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0122","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/jcp.30751","article-title":"Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: mechanisms of initiation, progression, and drug sensitivity","volume":"237","author":"Mahabady","year":"2022","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ajps.2025.101068_bib0123","article-title":"Chitosan- and hyaluronic acid-based nanoarchitectures in phototherapy: combination cancer chemotherapy, immunotherapy and gene therapy","volume":"273","author":"Wang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.ajps.2025.101068_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102400","article-title":"In vivo inhibition of angiogenesis by htsFLT01\/MiRGD nano complex","volume":"56","author":"Khoshandam","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ajps.2025.101068_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155795","article-title":"The functional role of LncRNA HOXA-AS2 in multiple human cancers","volume":"266","author":"Khoshandam","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ajps.2025.101068_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216867","article-title":"Autophagy flux in bladder cancer: cell death crosstalk, drug and nanotherapeutics","volume":"591","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajps.2025.101068_bib0127","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216857","article-title":"Dysregulation of autophagy in gastric carcinoma: pathways to tumor progression and resistance to therapy","volume":"591","author":"Wen","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajps.2025.101068_bib0128","article-title":"CRISPR\/Cas: advances, limitations, and applications for precision cancer research","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-021-01431-6","article-title":"Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0130","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","article-title":"In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells","volume":"11","author":"Martinez-Lage","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ajps.2025.101068_bib0131","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.14622","article-title":"Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review","volume":"40","author":"Kontomanolis","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0132","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1273994","article-title":"Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling","volume":"14","author":"Ravichandran","year":"2023","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0133","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","article-title":"CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer","volume":"27","author":"Vaghari-Tabari","year":"2022","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.ajps.2025.101068_bib0134","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1284610","article-title":"Genome-wide CRISPR\/Cas9 screening for drug resistance in tumors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajps.2025.101068_bib0135","article-title":"CRISPR\/Cas9: role of genome editing in cancer immunotherapy","volume":"10","author":"Vimal","year":"2024","journal-title":"Oral Oncol Rep"},{"key":"10.1016\/j.ajps.2025.101068_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115242","article-title":"Molecular landscape of LncRNAs in bladder cancer: from drug resistance to novel LncRNA-based therapeutic strategies","volume":"165","author":"Mehmandar-Oskuie","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0137","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-024-00857-z","article-title":"Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence","volume":"21","author":"Zhang","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0138","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s42003-023-05052-1","article-title":"CRISPR prime editing for unconstrained correction of oncogenic KRAS variants","volume":"6","author":"Jang","year":"2023","journal-title":"Commun Biol"},{"issue":"17","key":"10.1016\/j.ajps.2025.101068_bib0139","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-21-2519","article-title":"Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing","volume":"82","author":"Sayed","year":"2022","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ajps.2025.101068_bib0140","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.3390\/genes11060704","article-title":"Therapeutic editing of the TP53 gene: is CRISPR\/Cas9 an option?","volume":"11","author":"Mirgayazova","year":"2020","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0141","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.3390\/biomedicines12010238","article-title":"CRISPR\/Cas9-mediated gene therapy for glioblastoma: a scoping review","volume":"12","author":"Begagi\u0107","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0142","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45964-w","article-title":"CRISPR\/Cas9-mediated knock-in of BRCA1\/2 mutations restores response to olaparib in pancreatic cancer cell lines","volume":"13","author":"Witz","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0143","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/genes12050723","article-title":"New insights into the therapeutic applications of CRISPR\/Cas9 genome editing in breast cancer","volume":"12","author":"Ahmed","year":"2021","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0144","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13046-023-02901-z","article-title":"CRISPR\/Cas9: a powerful tool in colorectal cancer research","volume":"42","author":"Hu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0145","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1309175","article-title":"Engineering CRISPR\/Cas9 therapeutics for cancer precision medicine","volume":"15","author":"Sharma","year":"2024","journal-title":"Front Genet"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0146","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.drudis.2019.02.011","article-title":"CRISPR\/Cas9: a powerful tool for identification of new targets for cancer treatment","volume":"24","author":"Liu","year":"2019","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.ajps.2025.101068_bib0147","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1002\/cti2.1286","article-title":"Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy","volume":"10","author":"Afolabi","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.ajps.2025.101068_bib0148","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.755053","article-title":"Evolution of molecular targeted cancer therapy: mechanisms of drug resistance and novel opportunities identified by CRISPR-Cas9 screening","volume":"12","author":"Hou","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0149","first-page":"1031","article-title":"CRISPR screen in cancer: status quo and future perspectives","volume":"11","author":"He","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0150","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.2147\/IJN.S424872","article-title":"Innovative strategies of reprogramming immune system cells by targeting CRISPR\/Cas9-based genome-editing tools: a new era of cancer management","volume":"18","author":"Allemailem","year":"2023","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.ajps.2025.101068_bib0151","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11569-016-0259-0","article-title":"CRISPR\/Cas9 genome editing\u2013new and old ethical issues arising from a revolutionary technology","volume":"10","author":"Baumann","year":"2016","journal-title":"Nanoethics"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0152","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: fulfilling the promise of therapeutic genome editing","volume":"38","author":"van Haasteren","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"6629","key":"10.1016\/j.ajps.2025.101068_bib0153","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0154","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12951-023-02139-z","article-title":"A potential paradigm in CRISPR\/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles","volume":"21","author":"Feng","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.ajps.2025.101068_bib0155","first-page":"1","article-title":"Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells","volume":"7","author":"Stranford","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.ajps.2025.101068_bib0156","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.2147\/IJN.S199104","article-title":"Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR-Cas9","volume":"14","author":"Hosseini","year":"2019","journal-title":"Int J Nanomed"},{"issue":"10","key":"10.1016\/j.ajps.2025.101068_bib0157","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.242636","article-title":"The lumiptosome, an engineered luminescent form of the apoptosome can report cell death by using the same Apaf-1 dependent pathway","volume":"133","author":"Hosseini","year":"2020","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ajps.2025.101068_bib0158","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.10.061","article-title":"Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery","volume":"352","author":"Wang","year":"2022","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.ajps.2025.101068_bib0159","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1021\/acsabm.4c00103","article-title":"Optimizing transfection efficiency in CAR-T cell manufacturing through multiple administrations of lipid-based nanoparticles","volume":"7","author":"Giulimondi","year":"2024","journal-title":"ACS Appl Bio Mater"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/pharmaceutics15030984","article-title":"The CRISPR\/Cas9 system delivered by extracellular vesicles","volume":"15","author":"Zhu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ajps.2025.101068_bib0161","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0162","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103981","article-title":"Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy","volume":"29","author":"Dai","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ajps.2025.101068_bib0163","article-title":"Nanoliposomes for doxorubicin delivery: reversing drug resistance, stimuli-responsive carriers and clinical translation","volume":"80","author":"Hashemi","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"issue":"11","key":"10.1016\/j.ajps.2025.101068_bib0164","doi-asserted-by":"crossref","first-page":"e6861","DOI":"10.1002\/aoc.6861","article-title":"Preparation and evaluation of bismuth sulfide and magnetite-based theranostic nanohybrid as drug carrier and dual MRI\/CT contrast agent","volume":"36","author":"Nosrati","year":"2022","journal-title":"Appl Organomet Chem"},{"key":"10.1016\/j.ajps.2025.101068_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.115673","article-title":"Gold nanostructure-mediated delivery of anticancer agents: biomedical applications, reversing drug resistance, and stimuli-responsive nanocarriers","volume":"225","author":"Entezari","year":"2023","journal-title":"Environ Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0166","article-title":"Viral vectors for the delivery of CRISPR components: advances and challenges","volume":"10","author":"Mengstie","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0167","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0168","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41587-021-01009-z","article-title":"Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus","volume":"40","author":"Kim","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajps.2025.101068_bib0169","article-title":"Exploring advanced CRISPR delivery technologies for therapeutic genome editing","volume":"4","author":"Rostami","year":"2024","journal-title":"Small Sci"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"24","key":"10.1016\/j.ajps.2025.101068_bib0171","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202306432","article-title":"Magnetic nanoparticle-assisted non-viral CRISPR-Cas9 for enhanced genome editing to treat Rett syndrome","volume":"11","author":"Cho","year":"2024","journal-title":"Adv Sci"},{"key":"10.1016\/j.ajps.2025.101068_bib0172","article-title":"CRISPR-Cas9 based non-viral approaches in nanoparticle elicited therapeutic delivery","volume":"76","author":"Rani","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0173","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1109\/TBME.2022.3149530","article-title":"Knock-in of a large reporter gene via the high-throughput microinjection of the CRISPR\/Cas9 system","volume":"69","author":"Chen","year":"2022","journal-title":"IEEE Trans Biomed Eng"},{"issue":"17","key":"10.1016\/j.ajps.2025.101068_bib0174","doi-asserted-by":"crossref","first-page":"16412","DOI":"10.1021\/acsnano.2c12261","article-title":"Nonviral delivery of CRISPR-Cas9 using protein-agnostic, high-loading porous silicon and polymer nanoparticles","volume":"17","author":"Fletcher","year":"2023","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ajps.2025.101068_bib0175","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajps.2025.101068_bib0176","article-title":"Lipids and lipid derivatives for delivery of the CRISPR\/Cas9 system","volume":"78","author":"Madhi","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0177","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1021\/acs.nanolett.2c04374","article-title":"Cellular delivery of large functional proteins and protein-nucleic acid constructs via localized electroporation","volume":"23","author":"Pathak","year":"2023","journal-title":"Nano Lett"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0178","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0179","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09205063.2022.2121592","article-title":"Lipid-based nanocarrier mediated CRISPR\/Cas9 delivery for cancer therapy","volume":"34","author":"Aziz","year":"2023","journal-title":"J Biomater Sci Polym Ed"},{"key":"10.1016\/j.ajps.2025.101068_bib0180","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle delivery of CRISPR\/Cas9 for genome editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.ajps.2025.101068_bib0181","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120580","article-title":"PLGA-nanoparticles for intracellular delivery of the CRISPR-complex to elevate fetal globin expression in erythroid cells","volume":"268","author":"Cruz","year":"2021","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.ajps.2025.101068_bib0182","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1007\/s12033-022-00514-z","article-title":"BSA-PEI nanoparticle mediated efficient delivery of CRISPR\/Cas9 into MDA-MB-231 cells","volume":"64","author":"Rahimi","year":"2022","journal-title":"Mol Biotechnol"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0183","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ajps.2025.101068_bib0184","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120282","article-title":"Overcoming the delivery problem for therapeutic genome editing: current status and perspective of non-viral methods","volume":"258","author":"Mashel","year":"2020","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0185","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1570162X17666191025112918","article-title":"Designer nucleases: gene-editing therapies using CCR5 as an emerging target in HIV","volume":"17","author":"Almeida","year":"2019","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0186","article-title":"Antiretrovirals to CCR5 CRISPR\/Cas9 gene editing-a paradigm shift chasing an HIV cure","volume":"248","author":"Khan","year":"2023","journal-title":"Clin Immunol"},{"issue":"23","key":"10.1016\/j.ajps.2025.101068_bib0187","first-page":"e91","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Meisel","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2025.101068_bib0188","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0189","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-023-40901-x","article-title":"Whole genomic analysis reveals atypical non-homologous off-target large structural variants induced by CRISPR-Cas9-mediated genome editing","volume":"14","author":"Tsai","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajps.2025.101068_bib0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pbiomolbio.2022.05.001","article-title":"Decrypting the mechanistic basis of CRISPR\/Cas9 protein","volume":"172","author":"Panda","year":"2022","journal-title":"Prog Biophys Mol Biol"},{"issue":"7794","key":"10.1016\/j.ajps.2025.101068_bib0191","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ajps.2025.101068_bib0192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0193","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.ajps.2025.101068_bib0194","first-page":"1","article-title":"A scoping review on the ethical issues in the use of CRISPR-Cas9 in the creation of human disease models","volume":"17","author":"RF","year":"2023","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"10.1016\/j.ajps.2025.101068_bib0195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11569-022-00425-y","article-title":"Ethics and genomic editing using the CRISPR-Cas9 technique: challenges and conflicts","volume":"16","author":"Lorenzo","year":"2022","journal-title":"Nanoethics"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0196","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1242\/dev.139683","article-title":"Towards a CRISPR view of early human development: applications, limitations and ethical concerns of genome editing in human embryos","volume":"144","author":"Plaza Reyes","year":"2017","journal-title":"Development"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0197","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.3390\/ijms24076261","article-title":"Current bioinformatics tools to optimize CRISPR\/Cas9 experiments to reduce off-target effects","volume":"24","author":"Naeem","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ajps.2025.101068_bib0198","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902312","article-title":"CRISPR\/Cas systems in genome editing: methodologies and tools for sgRNA design, off-target evaluation, and strategies to mitigate off-target effects","volume":"7","author":"Manghwar","year":"2020","journal-title":"Adv Sci"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0199","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1038\/s41467-022-30515-0","article-title":"CRISPR\/Cas9 gRNA activity depends on free energy changes and on the target PAM context","volume":"13","author":"Corsi","year":"2022","journal-title":"Nat Commun"},{"issue":"6096","key":"10.1016\/j.ajps.2025.101068_bib0200","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0201","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/nar\/gkac192","article-title":"CRISPR\u2013Cas9 gRNA efficiency prediction: an overview of predictive tools and the role of deep learning","volume":"50","author":"Konstantakos","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0202","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0203","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.7150\/thno.71144","article-title":"CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives","volume":"12","author":"Chan","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ajps.2025.101068_bib0204","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.ajps.2025.101068_bib0205","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1039\/D1BM01658J","article-title":"Non-viral delivery of the CRISPR\/Cas system: DNA versus RNA versus RNP","volume":"10","author":"Lin","year":"2022","journal-title":"Biomater Sci"},{"issue":"19","key":"10.1016\/j.ajps.2025.101068_bib0206","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207512","article-title":"CRISPR\/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective","volume":"10","author":"Sahel","year":"2023","journal-title":"Adv Sci"},{"issue":"7","key":"10.1016\/j.ajps.2025.101068_bib0207","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1021\/acsami.1c17975","article-title":"Combinatorial approach of binary colloidal crystals and CRISPR activation to improve induced pluripotent stem cell differentiation into neurons","volume":"14","author":"Urrutia-Cabrera","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0208","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13287-024-03831-z","article-title":"Genome-scale CRISPR-Cas9 screening in stem cells: theories, applications and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"10.1016\/j.ajps.2025.101068_bib0209","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/dna4040030","article-title":"Genetic engineering in bacteria, fungi, and oomycetes, taking advantage of CRISPR","volume":"4","author":"Yang","year":"2024","journal-title":"DNA"},{"key":"10.1016\/j.ajps.2025.101068_bib0210","series-title":"Deep learning approaches for early diagnosis of neurodegenerative diseases","first-page":"25","article-title":"Introduction to neurodegenerative diseases","author":"Seyedebrahimi","year":"2024"},{"key":"10.1016\/j.ajps.2025.101068_bib0211","series-title":"Critical developments in cancer immunotherapy","author":"Sheykhhasan","year":"2024"},{"key":"10.1016\/j.ajps.2025.101068_bib0212","first-page":"1","article-title":"FOXR2 in cancer development: emerging player and therapeutic opportunities","volume":"30","author":"Yang","year":"2024","journal-title":"Oncol Res"},{"key":"10.1016\/j.ajps.2025.101068_bib0213","series-title":"Critical developments in cancer immunotherapy","first-page":"33","article-title":"Advancement in \u201coff-the-shelf\u201d CAR T-cell therapy for cancer immunotherapy","author":"Sheykhhasan","year":"2024"},{"issue":"8","key":"10.1016\/j.ajps.2025.101068_bib0214","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1002\/mco2.672","article-title":"CRISPR technology in human diseases","volume":"5","author":"Feng","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.ajps.2025.101068_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgg.2023.12.008","article-title":"Gene therapy and gene editing strategies in inherited blood disorders","volume":"51","author":"Song","year":"2024","journal-title":"J Genet Genomics"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0216","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0217","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2177088","article-title":"CRISPR\/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients","volume":"12","author":"Tian","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ajps.2025.101068_bib0218","first-page":"1","article-title":"Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations","volume":"8","author":"Ho\u0142ubowicz","year":"2024","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.ajps.2025.101068_bib0219","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR ethics: moral considerations for applications of a powerful tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J Mol Biol"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087625000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087625000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:38:56Z","timestamp":1767011936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087625000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":219,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1818087625000522"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2025.101068","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating CRISPR\/Cas technology with clinical trials: Principles, progress and challenges","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2025.101068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Shenyang Pharmaceutical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101068"}}